Physician profile
David E Korber
NPI 1720042088
$10,728.38
in general payments reported to CMS, 2019-2025
23 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $335 · 2021: $1,931 · 2022: $2,297 · 2023: $2,557 · 2024: $1,666 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,415 · Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,415.45 |
| Food and Beverage | $1,203.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,594.10 | 2022-2025 | |
| Allergan, INC. | $3,495.39 | 2020-2023 | |
| Alcon Vision LLC | $960.39 | 2019-2025 | Simbrinza, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $272.27 | 2022-2023 | Vyzulta |
| Aerie Pharmaceuticals, INC. | $267.95 | 2020-2021 | |
| Sight Sciences, INC. | $208.12 | 2019-2024 | Omni Surgical System |
| Ivantis, INC | $136.52 | 2019 | |
| Eyevance Pharmaceuticals LLC | $113.02 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $110.61 | 2019 | |
| Kala Pharmaceuticals, INC. | $97.36 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.80 | 2019-2021 | |
| Rxsight INC | $65.09 | 2021 | |
| Sun Pharmaceutical Industries INC. | $62.11 | 2022-2025 | Cequa |
| Shire North American Group INC | $45.38 | 2019 | |
| New World Medical,INC. | $39.92 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.98 | 2019 | |
| Oyster Point Pharma, INC. | $33.73 | 2022 | |
| Dompe US, INC. | $27.89 | 2025 | Oxervate |
| Harrow Eye, LLC | $27.23 | 2024 | Vevye |
| Glaukos Corporation | $20.11 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $13.04 | 2022 | |
| Ocular Therapeutix, INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Korber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.